98 related articles for article (PubMed ID: 35738828)
1. Impact of APOL1 kidney risk variants on glomerular transcriptomes.
Kopp JB; Heymann J
Kidney Int; 2022 Jul; 102(1):16-19. PubMed ID: 35738828
[TBL] [Abstract][Full Text] [Related]
2. APOL1 Kidney Disease Risk Variants: An Evolving Landscape.
Dummer PD; Limou S; Rosenberg AZ; Heymann J; Nelson G; Winkler CA; Kopp JB
Semin Nephrol; 2015 May; 35(3):222-36. PubMed ID: 26215860
[TBL] [Abstract][Full Text] [Related]
3. A glomerular transcriptomic landscape of apolipoprotein L1 in Black patients with focal segmental glomerulosclerosis.
McNulty MT; Fermin D; Eichinger F; Jang D; Kretzler M; Burtt NP; Pollak MR; Flannick J; Weins A; Friedman DJ; ; Sampson MG
Kidney Int; 2022 Jul; 102(1):136-148. PubMed ID: 34929253
[TBL] [Abstract][Full Text] [Related]
4. APOL1 nephropathy: from gene to mechanisms of kidney injury.
Kruzel-Davila E; Wasser WG; Aviram S; Skorecki K
Nephrol Dial Transplant; 2016 Mar; 31(3):349-58. PubMed ID: 25561578
[TBL] [Abstract][Full Text] [Related]
5. Kidney-disease-associated variants of Apolipoprotein L1 show gain of function in cation channel activity.
Bruno J; Edwards JC
J Biol Chem; 2021; 296():100238. PubMed ID: 33380423
[TBL] [Abstract][Full Text] [Related]
6. APOL1 Nephropathy Risk Variants Through the Life Course: A Review.
Itoku A; Isaac J; Wilson S; Reidy K; Kaskel F
Am J Kidney Dis; 2024 Jul; 84(1):102-110. PubMed ID: 38341125
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein L1 nephropathies: 2017 in review.
Kopp JB; Roshanravan H; Okamoto K
Curr Opin Nephrol Hypertens; 2018 May; 27(3):153-158. PubMed ID: 29389775
[TBL] [Abstract][Full Text] [Related]
8. One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants.
Kopp JB; Rosenberg AZ
Adv Anat Pathol; 2019 May; 26(3):215-219. PubMed ID: 30624253
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein L1 and mechanisms of kidney disease susceptibility.
Bruggeman LA; Sedor JR; O'Toole JF
Curr Opin Nephrol Hypertens; 2021 May; 30(3):317-323. PubMed ID: 33767059
[TBL] [Abstract][Full Text] [Related]
10. The Relationship between APOL1 Structure and Function: Clinical Implications.
Madhavan SM; Buck M
Kidney360; 2021 Jan; 2(1):134-140. PubMed ID: 35368828
[TBL] [Abstract][Full Text] [Related]
11. Arrest of the true culprit and acquittal of the innocent? Genetic revelations charge APOL1 variants with kidney disease susceptibility.
Zenker M; Mertens PR
Int Urol Nephrol; 2010 Dec; 42(4):1131-4. PubMed ID: 21080072
[No Abstract] [Full Text] [Related]
12. Profiling
Liu E; Radmanesh B; Chung BH; Donnan MD; Yi D; Dadi A; Smith KD; Himmelfarb J; Li M; Freedman BS; Lin J
Kidney360; 2020 Mar; 1(3):203-215. PubMed ID: 32656538
[TBL] [Abstract][Full Text] [Related]
13. APOL1 at 10 years: progress and next steps.
Freedman BI; Kopp JB; Sampson MG; Susztak K
Kidney Int; 2021 Jun; 99(6):1296-1302. PubMed ID: 33794228
[TBL] [Abstract][Full Text] [Related]
14. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.
Bruggeman LA; Wu Z; Luo L; Madhavan SM; Konieczkowski M; Drawz PE; Thomas DB; Barisoni L; Sedor JR; O'Toole JF
J Am Soc Nephrol; 2016 Dec; 27(12):3600-3610. PubMed ID: 27026370
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.
Lannon H; Shah SS; Dias L; Blackler D; Alper SL; Pollak MR; Friedman DJ
Kidney Int; 2019 Dec; 96(6):1303-1307. PubMed ID: 31611067
[TBL] [Abstract][Full Text] [Related]
16. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
[TBL] [Abstract][Full Text] [Related]
17. Dilemmas and challenges in apolipoprotein L1 nephropathy research.
Kruzel-Davila E; Skorecki K
Curr Opin Nephrol Hypertens; 2019 Jan; 28(1):77-86. PubMed ID: 30431460
[TBL] [Abstract][Full Text] [Related]
18. APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.
Fu Y; Zhu JY; Richman A; Zhang Y; Xie X; Das JR; Li J; Ray PE; Han Z
J Am Soc Nephrol; 2017 Apr; 28(4):1106-1116. PubMed ID: 27864430
[TBL] [Abstract][Full Text] [Related]
19. A Brief History of APOL1: A Gene Evolving.
Friedman DJ
Semin Nephrol; 2017 Nov; 37(6):508-513. PubMed ID: 29110757
[TBL] [Abstract][Full Text] [Related]
20. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.
Tzur S; Rosset S; Shemer R; Yudkovsky G; Selig S; Tarekegn A; Bekele E; Bradman N; Wasser WG; Behar DM; Skorecki K
Hum Genet; 2010 Sep; 128(3):345-50. PubMed ID: 20635188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
